Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

Author(s):

Nicole Chase, MD, FAAP, FACAAI, FAAAAI,S. Shahzad Mustafa, MD

The key opinion leaders explore the utilization of biomarkers in guiding the treatment of severe or uncontrolled asthma, discussing the specific role of eosinophils in informing therapeutic decision-making for patients with challenging asthma cases.

EP: 1.External Factors and Seasonality of Asthma

EP: 2.Endotypes and Phenotypes in Asthma

EP: 3.Type 2 Inflammation and Biomarkers in Asthma

EP: 4.Moderate/Severe/Uncontrolled Asthma Classification

EP: 5.Thinking About Endotypes when Managing Asthma

EP: 6.Use of Oral Corticosteroids in Asthma

EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma

EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma

Now Viewing

EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

EP: 10.Biologics in Asthma

EP: 11.GINA Guidelines and Biologics for Treatment of Asthma

EP: 12.Use of Biologics for Asthma in Patients with Allergies

EP: 13.Treatment of Asthma in Pediatric Patients

EP: 14.Atopic March in Pediatric Patients

EP: 15.Use of Biologics in Pediatric Patients and Conversations with Parents

EP: 16.Biologic Options in Pediatric Asthma

EP: 17.Advice for Clinicians Managing Asthma

Video content above is prompted by the following question(s):

Which biomarkers do you use to guide treatment of severe or uncontrolled asthma?
What factors can change eosinophil levels?
- How often are these factors considered when treating asthma?